PharmaShots

MAY 26, 2023

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer Date: May 26, 2023 | Tags: Takeda, HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, Regulatory, Priority Review, US, FDA Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19 Date: (..)

Biosimilars 40

Biosimilars 40

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

Diabetes 40

Diabetes Biosimilars 40

PharmaShots

MARCH 31, 2023

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer Date: Mar 31, 2023 | Tags: PDS Biotech, PDS0101, Keytruda, pembrolizumab, Head, Neck Cancer, Clinical Trial, P-III, VERSATILE-003 Trial Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular (..)

Diabetes 40

Diabetes 40

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 40

Diabetes Immunity Immunization Biosimilars 40

Pharmaceutical Technology

JANUARY 17, 2023

Bimagrumab is of interest in the obesity space as it is a first-in-class therapy for obesity. Bimagrumab is an activin receptor type 2B (ACVR2B or EC 2.7.11.30) antagonist that offers a unique mechanism of action within the obesity market. Mounjaro is anticipated to launch in the US later this year or by early 2024.

Diabetes 52

Diabetes Hospitals 52

RX Note

JUNE 11, 2023

Certain lesions, such as nevi, milia, dermatofibroma, skin tags, pyogenic granuloma, keratosis pilaris, syringoma are more common in children and younger adults. Skin Tag Acrochordons, commonly known as skin tags, are an outgrowth of normal skins (soft and fleshy).

Diabetes 52

Diabetes Community Pharmacies 52

Fuld & Company Blog

MARCH 27, 2023

However, there are still plenty of people who are willing to pay out of pocket for semaglutide, despite the high price tag and, hence, could opt to pay for either Wegovy or Ozempic. With trials showing potential weight loss of 10% to 15% , for many, the price tag of $1,500 per month is well worth it.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

PharmD Live

JANUARY 25, 2022

Obesity is rising in the more sedentary aging population, an extra layer of risk for Medicare patients. Diabetes 2, low quality of life, cardiac-related illnesses, osteoarthritis, and more are caused or exacerbated by obesity. Eidenberg additionally received a Healthcare Management MBA from Walden University. Joseph Guglielmo, PharmD.

Adverse Reactions 52

Adverse Reactions Doctor of Pharmacy Diabetes Communication 52

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. were obese, and 9.2%

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. were obese, and 9.2%

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

Health and Personal Care Stores 40

Health and Personal Care Stores Mayo Clinic Hospitals Specialty Pharmacies 40